Most Viewed
1:31Pooled Analysis of RECORD1, 2, and 3
2:34Results of the Landmark RECORD Programme
2:28'Xarelto' (rivaroxaban) - Most Studied Oral Direct Factor Xa Inhibitor
1:11Desirable Characteristics of an Anticoagulant
1:312:342:281:11Now Playing:
2:36Xarelto Countdown
Related Videos:
1:30The RECORD Programme
1:44Potential Health Economics Benefits of 'Xarelto'
1:06Challenging the Burden of Mortality in ACS
1:11Desirable Characteristics of an Anticoagulant
0:50Mode of Action of ‘Xarelto’
2:34Results of the Landmark RECORD Programme
2:28'Xarelto' (rivaroxaban) - Most Studied Oral Direct Factor Xa Inhibitor
1:08Widening the Gap Between Risk and Benefit
0:24Venous Thrombus Formation and Break Away
1:31Pooled Analysis of RECORD1, 2, and 3
